

CITATION REPORT

List of articles citing

Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium

DOI: 10.1016/j.hrthm.2019.04.008
Heart Rhythm, 2019, 16, 1374-1382.

Source: <https://exaly.com/paper-pdf/73542978/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
45	Real-Life Insight Into Ibrutinib Cardiovascular Events: Defining the Loose Ends. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1679-1681	15.1	4
44	Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. <i>Wiener Klinische Wochenschrift</i> , 2020 , 132, 97-109	2.3	4
43	Electrophysiology Translational Considerations in Cardio-Oncology: QT and Beyond. <i>Journal of Cardiovascular Translational Research</i> , 2020 , 13, 390-401	3.3	7
42	Deciphering the Electrophysiological Mechanisms for Ibrutinib-Induced Ventricular Arrhythmias. <i>JACC: CardioOncology</i> , 2020 , 2, 630-631	3.8	0
41	Acute Effects of Ibrutinib on Ventricular Arrhythmia in Spontaneously Hypertensive Rats. <i>JACC: CardioOncology</i> , 2020 , 2, 614-629	3.8	4
40	Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. <i>Circulation</i> , 2020 , 142, 2443-2455	16.7	43
39	Full Issue PDF. <i>JACC: CardioOncology</i> , 2020 , 2, I-CXLI	3.8	
38	Cardiotoxicity of Novel Targeted Hematological Therapies. <i>Life</i> , 2020 , 10,	3	6
37	Onkologische Kardiologie. <i>Kardiologe</i> , 2020 , 14, 267-293	0.6	1
36	Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1197-1222	6.1	27
35	Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 103010	7	12
34	Electrocardiographic Changes Associated With Ibrutinib Exposure. <i>Cancer Control</i> , 2020 , 27, 1073274820221808	2.2	1
33	Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors. <i>Current Treatment Options in Oncology</i> , 2020 , 21, 67	5.4	3
32	Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation. <i>Redox Biology</i> , 2020 , 30, 101432	11.3	23
31	Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib. <i>Echocardiography</i> , 2021 , 38, 81-88	1.5	1
30	Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis. <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , 2021 , 59, 270-277	1.5	
29	Severe hypercalcemia in a patient with chronic lymphocytic leukemia and non-small cell lung carcinoma: A case report. <i>Medicine (United States)</i> , 2021 , 100, e24982	1.8	

28	The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	7
27	Transcriptional factors in calcium mishandling and atrial fibrillation development. <i>Pflugers Archiv European Journal of Physiology</i> , 2021 , 473, 1177-1197	4.6	1
26	Connexin45 (GJC1) loss-of-function mutation contributes to familial atrial fibrillation and conduction disease. <i>Heart Rhythm</i> , 2021 , 18, 684-693	6.7	8
25	Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. <i>Progress in Cardiovascular Diseases</i> , 2021 , 66, 28-36	8.5	4
24	Quercetin prevents isoprenaline-induced myocardial fibrosis by promoting autophagy via regulating miR-223-3p/FOXO3. <i>Cell Cycle</i> , 2021 , 20, 1253-1269	4.7	6
23	Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2693-2716	15.1	7
22	High-grade heart block associated with ibrutinib therapy. <i>HeartRhythm Case Reports</i> , 2021 , 7, 391-394	1	1
21	RIPK3-Mediated Necroptosis in Diabetic Cardiomyopathy Requires CaMKII Activation. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 6617816	6.7	2
20	Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2021 , 144, e41-e55	16.7	6
19	Modulated Calcium Homeostasis and Release Events Under Atrial Fibrillation and Its Risk Factors: A Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 662914	5.4	2
18	Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3453-3462	2.2	6
17	Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	3
16	Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database. <i>Frontiers in Pharmacology</i> , 2021 , 12, 769315	5.6	3
15	Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis. <i>Journal of the American Heart Association</i> , 2021 , 10, e022369	6	1
14	Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib. <i>Cardio-Oncology</i> , 2021 , 7, 38	2.8	1
13	Ibrutinib-associated atrial fibrillation treatment with catheter ablation. <i>HeartRhythm Case Reports</i> , 2021 , 7, 713-716	1	0
12	Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 758010	5.4	0
11	Empagliflozin Ameliorates Ouabain-Induced Na and Ca Dysregulations in Ventricular Myocytes in an Na-Dependent Manner.. <i>Cardiovascular Drugs and Therapy</i> , 2022 , 1	3.9	2

10	Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.. <i>Expert Review of Hematology</i> , 2022 ,	2.8	2
9	Febuxostat Increases Ventricular Arrhythmogenesis Through Calcium Handling Dysregulation in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Toxicological Sciences</i> ,	4.4	0
8	Cardiac fibrosis in oncologic therapies. 2022 , 29, 100575		0
7	Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Volume 16, 3225-3239		0
6	Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database. 13,		0
5	The Impact of Sleep Disturbance on Gut Microbiota, Atrial Substrate, and Atrial Fibrillation Inducibility in Mice: A Multi-Omics Analysis. 2022 , 12, 1144		0
4	Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics. 2023 , 101591		2
3	Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. 2023 , 25, 269-280		0
2	Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study.		0
1	Kinase Inhibitors and Atrial Fibrillation. 2023 ,		0